Virulence Profiles and Genome-Wide Association Study for Ascochyta lentis Isolates Collected from Australian Lentil-Growing Regions

Ascochyta lentis, the causal organism of Ascochyta blight (AB) of lentil (Lens culinaris), has been shown to produce an avirulence effector protein that mediates AB resistance in certain lentil cultivars. The two known forms of the effector protein were identified from a biparental mapping population between isolates that have reciprocal virulence on 'PBA Hurricane XT' and 'Nipper'. The effector AlAvr1-1 was described for the PBA Hurricane XT-avirulent isolate P94-24 and AlAvr1-2 characterized in the PBA Hurricane XT-virulent isolate AlKewell. Here, we performed a genome-wide association study to identify other loci associated with AB for a differential set of lentil cultivars from a diverse panel of isolates collected in the Australian lentil-growing regions from 2013 to 2020. The chromosome 3 AlAvr1 locus was strongly associated with the PBA Hurricane XT, 'Indianhead', and Nipper disease responses, but one other genomic region on chromosome 11 was also associated with the Nipper disease trait. Our results corroborate earlier work that identified the AlAvr1 locus for field-collected isolates that span the period before release and after widespread adoption of PBA Hurricane XT. A multiplex PCR assay was developed to differentiate the genes AlAvr1-1 and AlAvr1-2 to predict PBA Hurricane XT avirulence and pathotype designation in the diversity panel. Increasing numbers of the PBA Hurricane XT-virulent pathotype 2 isolates across that time indicate strong selection for isolates with the AlAvr1-2 allele. Furthermore, one other region of the A. lentis genome may contribute to the pathogen-host interaction for lentil AB.

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

BACKGROUND

Breast cancer is the most frequently diagnosed cancer and the leading reason for cancer-related death among women. Neoadjuvant treatment with dual-HER2 (human epidermal growth factor receptor 2) blockade has shown promising effects in this regard. The present study aimed to compare the efficacy and safety of a proposed pertuzumab biosimilar with the reference pertuzumab.

METHODS

This randomized, phase III, multicenter, equivalency clinical trial was conducted on chemotherapy-naive women with HER2-positive breast cancer. Patients were randomly assigned (1:1) to receive six cycles of either P013 (CinnaGen, Iran) or the originator product (Perjeta, Roche, Switzerland) along with trastuzumab, carboplatin, and docetaxel every 3 weeks. Patients were stratified by cancer type (operable, locally advanced, inflammatory) and hormone receptor status. The primary endpoint was breast pathologic complete response (bpCR). Secondary endpoints included comparisons of total pCR, overall response rate (ORR), breast-conserving surgery (BCS), safety, and immunogenicity.

RESULTS

Two hundred fourteen patients were randomized to treatment groups. bpCR rate in the per-protocol population was 67.62% in the P013 and 71.57% in the reference drug groups. Based on bpCR, P013 was equivalent to the reference pertuzumab with a mean difference of - 0.04 (95% CI: - 0.16, 0.09). Secondary endpoints were also comparable between the two groups.

CONCLUSIONS

The proposed biosimilar P013 was equivalent to the reference product in terms of efficacy. The safety of both medications was also comparable.

Poultry by-product meal as a replacement to xylose-treated soybean meal in diet of early- to mid-lactation Holstein cows

The objectives were to compare the effectiveness of poultry by-product meal (PBM) with xylose-treated soybean meal (x-SBM) as a conventional protein source and rumen-undegraded protein (RUP):rumen-degraded protein (RDP) ratio on nutrient digestibility, nitrogen metabolism, and production of early- to mid-lactation Holsteins. Twelve multiparous cows averaging (mean ± SD) 50 ± 9 days in milk were randomly assigned to a replicated 4 × 4 Latin square design within a 2 × 2 factorial arrangement of treatments. Each period was 28 days in length. Treatments were RUP sources (PBM or x-SBM) with either a high or a low RUP:RDP ratio (high ratio = 40:60 or low ratio = 36:64; based on % of crude protein (CP)). Experimental diets were balanced to be similar in protein and energy contents (CP = 16.7% of DM; NEL = 1.67 Mcal/kg DM). Prior to diet formulation, an in situ pilot experiment was conducted to estimate the RUP fractions of x-SBM and PBM as 63.9% and 54.1% of CP, respectively. Treatments had no effect on ruminal pH and total volatile fatty acid (VFA) and molar percentage of individual VFAs. Treatments had no effect on total tract apparent digestibility of DM, OM, and neutral detergent fiber (NDF), with the exception of N that was greater in diets with a low RUP:RDP ratio (68.2 vs. 70.1% of DM). DM consumption was 0.70 kg/day higher when cows were fed PBM diet compared with x-SBM diet. No treatment effect was observed on milk yield and milk composition; however, milk protein yield and milk urea N were greater in cows fed PBM. Inclusion of PBM in the diet in substitution to x-SBM resulted in increased blood levels of urea N, cholesterol, and non-esterified fatty acid (NEFA). There was no interaction between the RUP source and the RUP:RDP ratio for urinary and fecal N excretion. Efficiency of N utilization expressed as milk N secretion as a proportion of N intake tended to be greater in cows fed PBM. Feeding diets with a low ratio of RUP:RDP increased efficiency of milk production expressed as milk yield as a proportion of total N excretion (fecal and urinary N). Feeding a diet with PBM supported milk production comparable with x-SBM and had positive effects on feed intake, milk protein yield, and milk N efficiency.

Effects of increasing diet fermentability on intake, digestion, rumen fermentation, blood metabolites and milk production of heat-stressed dairy cows

Heat stress is a major problem for dairy cows in hot climates, thus coping strategies are essential. This study evaluated the effects of increasing diet fermentability on intake, total tract digestibility, ruminal pH and volatile fatty acids (VFA) profile, blood metabolite profile and milk production and composition of lactating dairy cows managed under conditions of ambient heat stress. Nine multiparous cows (650 ± 56 kg BW; mean ± SD) averaging 102 ± 13 days in milk and producing 54 ± 6 kg/day were randomly assigned to a triplicate 3 × 3 Latin square. During each 21-day period, cows were offered one of three total mixed rations that varied in diet fermentability. The three levels of diet fermentability were achieved by increasing the proportion of pellets containing ground wheat and barley in the dietary DM from 11.7% (low), to 23.3% (moderate), and 35.0% (high) by replacing ground corn grain. Each period had 14 day of adaptation and 7 day of sampling. The ambient temperature-humidity index ( ≥ 72) indicated that the cows were in heat stress almost the entire duration of the study. Also, rectal temperature of cows was elevated at 39.2°C, another indication of heat stress. Increasing diet fermentability linearly decreased dry matter intake (22.8, 22.5, 21.8 kg/day for low, moderate and high, respectively; P ≤ 0.05) but increased non-fibre carbohydrate digestibility (P ≤ 0.05) and tended to increase digestibility of DM (P = 0.10) and crude protein (P = 0.06). As a result, the intake of digestible DM was not affected by the treatments. The production of 3.5% fat corrected milk (32.6, 33.7, and 31.5 kg/day) was quadratically (P ≤ 0.05) affected by diet fermentability with lower production for the high diet compared with the other two, which were similar. Rumen pH (ruminocentesis) and proportions of butyrate and isovalerate linearly decreased whereas propionate proportion linearly increased with increasing diet fermentability (P ≤ 0.05). The rumen concentration of NH3-N (11.0, 9.0, and 8.7 mg/dL) and blood concentration of urea linearly decreased with increasing diet fermentability (P ≤ 0.05). The activity of alkaline phosphatase increased (65.1, 83.2, and 84.9 U/l) and concentration of malondialdehyde decreased (2.39, 1.90 and 1.87 µmol/l) linearly with increasing diet fermentability (P ≤ 0.05), which indicated possible attenuation of the effects of oxidative stress with increasing diet fermentability. Overall, a modest increase of diet fermentability improved nitrogen metabolism, milk protein production and oxidative stress of heat-stressed dairy cows, but a further increase in diet fermentability decreased milk yield.

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer

Background:

The present study was aimed to evaluate the efficacy and safety of at least three cycles of Bevacizumab in combination with chemotherapy regimens, FOLFIRI or FOLFOX to treat liver metastatic colorectal cancer and improved response rates in these patients.

Materials and Methods:

In this non-randomized clinical trial, 38 patients were enrolled and followed for 12-weeks period of chemotherapy. Fifteen patients under treated with FOLOFX (Group I), 15 patients under treated with FOLOFIRI (Group II), 4 patients under treated with FOLOFX + Bevacizumab (Group III), and 34 patients under treated with FOLOFIRI + Bevacizumab (Group IV). Response to treatment was assessed in all patients as main endpoint. Patients in groups I and II, who did not response to treatment after 12 weeks of chemotherapy, were followed by groups III and IV regimens, respectively, for 12 weeks.

Results:

Overall response rate was 35% (19 of 54), and complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) rates in all patients were 18%, 17%, 35%, and 30%. PR, SD, and PD were different among groups, but no statistical significance was noted among groups (P-value >0.05). No patient achieved a CR in groups III and IV, although CR was observed in 4 patients (27%) and 6 patients (40%) in groups I and II, respectively. The rare of CR was statistically significant among studied groups (P-value = 0.013).

Conclusion:

Results showed that adding Bevacizumab to chemotherapy regimens, in patients who did not response to FOLFIRI or FOLFOX regimen, did not increase CR in these patients.

Preparation of graphene oxide by cyanuric chloride as an effective and non-corrosive oxidizing agent

In this work, we report a new method for the synthesis of graphene oxide (GO) using cyanuric chloride as a non-corrosive oxidizing agent.

WITHDRAWN: A Patient with Rheumatic Mitral Stenosis and an Atrial Myxoma

The publisher regrets that this was an accidental duplication of an article that has already been published in Eur. J. Echocardiogr., 4 (2003) 229-231, . The duplicate article has therefore been withdrawn.

Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial

OBJECTIVE

To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer's disease.

DESIGN

A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Iran.

METHODS

Patients with mild to moderate Alzheimer's disease aged between 65 and 80 years (n = 42; 18 women, 24 men) with a score of >or= 12 on the cognitive subscale of Alzheimer's disease assessment scale (ADAS-cog) and <or= 2 on the clinical dementia rating (CDR) were randomised to placebo or fixed dose of Melissa officinalis extract. The main efficacy measures were the change in the ADAS-cog and CDR-SB scores compared with baseline. Side effects were systematically recorded.

RESULTS

At four months, Melissa officinalis extract produced a significantly better outcome on cognitive function than placebo (ADAS-cog: df = 1, F = 6.93, p = 0.01; CDR: df = 1, F = 16.87, p < 0.0001). There were no significant differences in the two groups in terms of observed side effects except agitation, which was more common in the placebo group (p = 0.03).

CONCLUSIONS

Melissa officinalis extract is of value in the management of mild to moderate Alzheimer's disease and has a positive effect on agitation in such patients.

Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial

BACKGROUND

Alzheimer's disease is characterized by a slow, progressive decline in cognitive function and behaviour. Acetylcholine esterase inhibitors are the only agents approved by the Food and Drug Administration for the treatment of Alzheimer's disease. All other agents prescribed for the treatment of Alzheimer's disease are used on an off-label basis. Current research into new drugs is focused on agents that will prevent, slow down and/or halt the progress of the disease process. Salvia officinalis has been used in herbal medicine for many centuries. It has been suggested, on the basis of traditional medicine, its in vitro cholinergic binding properties and modulation of mood and cognitive performance in humans, that Salvia officinalis might potentially provide a novel natural treatment for Alzheimer's disease. The objective of this study was to assess the efficacy and safety of Salvia officinalis extract using a fixed dose (60 drops/day), in patients with mild to moderate Alzheimer's disease, over a 4-month period.

METHODS

This was a 4-month, parallel group, placebo-controlled trial undertaken in three centres in Tehran, Iran. Patients with mild to moderate Alzheimer's disease aged between 65 and 80 years (n = 42, 18 women) with a score of > or = 12 on the cognitive subscale of Alzheimer's Disease Assessment Scale (ADAS-cog) and < or = 2 on the Clinical Dementia Rating (CDR) were randomized to placebo or fixed dose of S. officinalis extract. Over the 16 weeks, the main efficacy measures were the change in the ADAS-cog and CDR-Sum of Boxes scores compared with baseline. In addition, side-effects were systematically recorded throughout the study using a checklist.

RESULTS

At 4 months, S. officinalis extract produced a significant better outcome on cognitive functions than placebo (ADAS-cog: F = 4.77, d.f. = 1, P = 0.03) (CDR-SB: F = 10.84, d.f. = 1, P < 0.003). There were no significant differences in the two groups in terms of observed side-effects except agitation that appears to be more frequent in the placebo group (P = 0.09).

CONCLUSIONS

The results of this study indicate the efficacy of S. officinalis extract in the management of mild to moderate Alzheimer's disease. Moreover, S. officinalis may well reduce agitation of patients but this needs to be confirmed.

Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam

OBJECTIVE

Passionflower (Passiflora incarnata) is a folk remedy for anxiety. A double-blind randomized trial compared the efficacy of Passiflora incarnata extract with oxazepam in the treatment of generalized anxiety disorder.

METHODS

The study was performed on 36 out-patients diagnosed with GAD using DSM IV criteria. Patients were allocated in a random fashion: 18 to the Passiflora extract 45 drops/day plus placebo tablet group, and 18 to oxazepam 30 mg/day plus placebo drops for a 4-week trial.

RESULTS

Passiflora extract and oxazepam were effective in the treatment of generalized anxiety disorder. No significant difference was observed between the two protocols at the end of trial. Oxazepam showed a rapid onset of action. On the other hand, significantly more problems relating to impairment of job performance were encountered with subjects on oxazepam.

CONCLUSION

The results suggest that Passiflora extract is an effective drug for the management of generalized anxiety disorder, and the low incidence of impairment of job performance with Passiflora extract compared to oxazepam is an advantage. A large-scale trial is justified.

Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial

OBJECTIVE

Clonidine-based therapies have been utilized as the main protocol for opiate detoxification for several years. However, detoxification with clonidine has its limitations, including lack of efficacy for mental symptoms. Accumulating evidence shows the efficacy of Passiflora incarnata extract in the management of anxiety. In our continuing study of traditional medicines, which have neurotropic effects, this plant had an anxiolytic effect, which may be used as an adjuvant agent in the detoxification of opiates by clonidine. We present the results of a double-blind randomized controlled trial of clonidine plus passiflora extract vs. clonidine plus placebo in the outpatient detoxification of 65 opiates addicts.

METHODS

A total of 65 opiates addicts were assigned randomly to treatment with passiflora extract plus clonidine tablet or clonidine tablet plus placebo drop during a 14-day double-blind clinical trial. All patients met the DSM IV criteria for opioid dependence. The fixed daily dose was 60 drops of passiflora extract and a maximum daily dose of 0.8 mg of clonidine administered in three divided doses. The severity of the opiate withdrawal syndrome was measured on days 0, 1, 2, 3, 4, 7 and 14 using the Short Opiate Withdrawal Scale (SOWS).

CONCLUSION

Both protocols were equally effective in treating the physical symptoms of withdrawal syndromes. However, the passiflora plus clonidine group showed a significant superiority over clonidine alone in the management of mental symptoms. These results suggested that passiflora extract may be an effective adjuvant agent in the management of opiate withdrawal. However, a larger study to confirm our results is warranted.